Geron’s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

News   Jun 13, 2007

 
Geron’s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
 
 
 

RELATED ARTICLES

PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.

READ MORE

New Speakers from Roche and Imperial College London Announced for SMi’s ADMET Event

News

SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.

READ MORE

Cell Technology Used to Treat Osteochondral Knee Defect

News

Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy